Palatin Technologies (PTN) Current Assets (2011 - 2026)
Palatin Technologies' (PTN) quarterly Current Assets came in at $12.8 million in Q1 2026, up 295.43% YoY from $3.2 million in Q1 2025, and down 26.81% on a QoQ basis from $17.5 million in Q4 2025.
Palatin Technologies (PTN) Current Assets (2011 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 15 years of Current Assets data on file, last reported at $12.8 million in Q1 2026.
- Quarterly Current Assets rose 295.43% year-over-year to $12.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.8 million (up 295.43% YoY) and the FY2025 annual result came in at $2.9 million, down 70.12% from the prior year.
- Current Assets fell to $12.8 million in Q1 2026, from $17.5 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $42.2 million in Q1 2022 to a low of $2.6 million in Q3 2024.
- A 5-year average of $15.7 million and a median of $12.2 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets slumped 73.36% — and 2025, when it jumped 375.99%.
- Tracing PTN's Current Assets over 5 years: stood at $30.6 million in 2022, then slumped by 59.92% to $12.2 million in 2023, then slumped by 70.03% to $3.7 million in 2024, then jumped by 375.99% to $17.5 million in 2025, then fell by 26.81% to $12.8 million in 2026.
- The last three Current Assets figures came in at $12.8 million (Q1 2026), $17.5 million (Q4 2025), and $8.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | 1.76 Bn |
| 10 | Palatin Technologies | 41.58 Mn | 41.58 Mn | - | 12.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.79 Mn |
| Dec 31, 2025 | 17.47 Mn |
| Sep 30, 2025 | 8.37 Mn |
| Jun 30, 2025 | 2.92 Mn |
| Mar 31, 2025 | 3.23 Mn |
| Dec 31, 2024 | 3.67 Mn |
| Sep 30, 2024 | 2.61 Mn |
| Jun 30, 2024 | 9.77 Mn |
| Mar 31, 2024 | 10.27 Mn |
| Dec 31, 2023 | 12.25 Mn |
| Sep 30, 2023 | 9.81 Mn |
| Jun 30, 2023 | 16.32 Mn |
| Mar 31, 2023 | 24.24 Mn |
| Dec 31, 2022 | 30.55 Mn |
| Sep 30, 2022 | 26.18 Mn |
| Jun 30, 2022 | 34.60 Mn |
| Mar 31, 2022 | 42.25 Mn |
| Dec 31, 2021 | 51.37 Mn |
| Sep 30, 2021 | 58.39 Mn |
| Jun 30, 2021 | 65.91 Mn |